Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
ANEW MEDICAL, INC. (NASDAQ: WENA) has announced two key goals for its cell and gene therapy development: enhancing healthy longevity potential and developing treatments for age-related and neurodegenerative diseases. The company has secured exclusive worldwide rights and patents for the secreted form of Klotho (s-KL), often called 'the anti-aging gene'. ANEW's hypothesis suggests that maintaining high Klotho levels leads to a long, healthy life, while depleted levels may cause neurodegenerative diseases.
ANEW plans to study blood samples from Okinawa centenarians, comparing them to a cohort with age-related disorders. The company has partnered with the Okinawa Centenarian Research Center for Longevity, including renowned scientists as advisors. ANEW aims to enter clinical trials soon and leverage its recent Nasdaq listing to expedite development of Klotho-based therapies.
ANEW MEDICAL, INC. (NASDAQ: WENA) ha annunciato due obiettivi principali per lo sviluppo della sua terapia cellulare e genica: potenziare il potenziale di longevità sana e sviluppare trattamenti per malattie legate all'età e neurodegenerative. L'azienda ha ottenuto diritti e brevetti mondiali esclusivi per la forma secretata di Klotho (s-KL), spesso chiamato 'il gene dell'antinvecchiamento'. L'ipotesi di ANEW suggerisce che mantenere alti livelli di Klotho porti a una vita lunga e sana, mentre livelli ridotti possono causare malattie neurodegenerative.
ANEW prevede di studiare campioni di sangue da centenari di Okinawa, confrontandoli con un gruppo di controllo affetto da disturbi legati all'età. L'azienda ha collaborato con il Centro di Ricerca per la Longevità di Okinawa per i Centenari, coinvolgendo scienziati rinomati come consulenti. ANEW mira a entrare in sperimentazioni cliniche a breve e a sfruttare la sua recente quotazione al Nasdaq per accelerare lo sviluppo di terapie basate su Klotho.
ANEW MEDICAL, INC. (NASDAQ: WENA) ha anunciado dos objetivos clave para el desarrollo de su terapia celular y génica: mejorar el potencial de longevidad saludable y desarrollar tratamientos para enfermedades relacionadas con la edad y neurodegenerativas. La empresa ha asegurado derechos y patentes exclusivos a nivel mundial para la forma secretada de Klotho (s-KL), a menudo llamado 'el gen anti-envejecimiento'. La hipótesis de ANEW sugiere que mantener altos niveles de Klotho conduce a una vida larga y saludable, mientras que niveles disminuidos pueden causar enfermedades neurodegenerativas.
ANEW planea estudiar muestras de sangre de centenarios de Okinawa, comparándolas con un grupo de control con trastornos relacionados con la edad. La empresa se ha asociado con el Centro de Investigación de Centenarios de Okinawa para la Longevidad, incluyendo a científicos renombrados como asesores. ANEW tiene como objetivo entrar en ensayos clínicos pronto y aprovechar su reciente cotización en Nasdaq para acelerar el desarrollo de terapias basadas en Klotho.
ANEW MEDICAL, INC. (NASDAQ: WENA)는 세포 및 유전자 치료 개발을 위한 두 가지 주요 목표를 발표했습니다: 건강한 장수 가능성 증대 및 노화 관련 질환과 신경퇴행성 질환에 대한 치료법 개발. 이 회사는 '항노화 유전자'라고 불리는 Klotho의 분비 형태(s-KL)에 대한 전 세계 독점 권리 및 특허를 확보했습니다. ANEW의 가설은 Klotho 수치를 높게 유지하면 길고 건강한 삶으로 이어지며, 고갈된 수치는 신경퇴행성 질환을 유발할 수 있다고 제안합니다.
ANEW는 오키나와의 백세인을 대상으로 혈액 샘플을 연구하고, 이들을 노화 관련 장애를 가진 집단과 비교할 계획입니다. 이 회사는 오키나와 장수 센터와 협력하며, 저명한 과학자들을 자문으로 포함하고 있습니다. ANEW는 곧 임상 시험에 참여할 계획이며, 최근의 나스닥 상장을 활용하여 Klotho 기반 치료 개발을 가속화할 것입니다.
ANEW MEDICAL, INC. (NASDAQ: WENA) a annoncé deux objectifs clés pour le développement de sa thérapie cellulaire et génique : améliorer le potentiel de longévité saine et développer des traitements pour les maladies liées à l'âge et neurodégénératives. La société a obtenu des droits mondiaux exclusifs et des brevets pour la forme secrétée du Klotho (s-KL), souvent appelée 'le gène de l'anti-âge'. L'hypothèse d'ANEW suggère que le maintien de niveaux élevés de Klotho conduit à une vie longue et saine, tandis que des niveaux réduits peuvent causer des maladies neurodégénératives.
ANEW prévoit d'étudier des échantillons de sang de centenaires d'Okinawa, en les comparant à un groupe de contrôle ayant des troubles liés à l'âge. L'entreprise s'est associée au Centre de recherche pour la longévité des centenaires d'Okinawa, en y incluant des scientifiques de renom comme conseillers. ANEW vise à entrer bientôt dans des essais cliniques et à tirer parti de son inscription récente au Nasdaq pour accélérer le développement de thérapies basées sur Klotho.
ANEW MEDICAL, INC. (NASDAQ: WENA) hat zwei wichtige Ziele für die Entwicklung seiner Zell- und Gentherapie angekündigt: die Verbesserung des Potenzials für gesundes Altern und die Entwicklung von Behandlungen für altersbedingte und neurodegenerative Krankheiten. Das Unternehmen hat sich exklusive weltweite Rechte und Patente für die sekretierte Form von Klotho (s-KL) gesichert, das oft als 'das Anti-Aging-Gen' bezeichnet wird. Die Hypothese von ANEW legt nahe, dass hohe Klotho-Spiegel zu einem langen, gesunden Leben führen, während verringerte Werte neurodegenerative Krankheiten verursachen können.
ANEW plant, Blutproben von Hundertjährigen aus Okinawa zu untersuchen und diese mit einer Kohorte von Personen mit altersbedingten Störungen zu vergleichen. Das Unternehmen hat mit dem Okinawa Centenarian Research Center for Longevity zusammengearbeitet und namhafte Wissenschaftler als Berater gewonnen. ANEW beabsichtigt, bald in klinische Studien zu starten und seine kürzliche Nasdaq-Notierung zu nutzen, um die Entwicklung von Klotho-basierten Therapien zu beschleunigen.
- Secured exclusive worldwide rights and patents for Klotho gene (s-KL) in major markets
- Partnership with Okinawa Centenarian Research Center for Longevity and renowned scientists as advisors
- Recent Nasdaq listing to expedite development programs
- Potential to enter clinical trials in the near future
- No current FDA approval for clinical trials
- Hypothesis on Klotho's role in longevity and disease prevention still needs further validation
Insights
ANEW's focus on the Klotho gene (s-KL) for healthy longevity and neurodegenerative diseases is intriguing. The company's exclusive worldwide rights and patents on s-KL provide a strong competitive advantage. Their planned study comparing Okinawan centenarians with those affected by neurodegenerative diseases could yield valuable insights into the role of Klotho in aging and disease. However, it's important to note that gene therapy is still an emerging field with many regulatory hurdles. The partnership with the Okinawa Centenarian Research Center adds credibility, but investors should be aware that the path to FDA approval and marketable therapies is typically long and uncertain in this sector.
ANEW's recent Nasdaq listing is a positive step, potentially improving access to capital for their ambitious research programs. However, investors should exercise caution. The company's focus on longevity and age-related diseases targets a massive potential market, but the road to profitability in biotech is often long and risky. Without specific financial figures or timelines for clinical trials, it's difficult to assess the company's near-term prospects. The partnership with renowned longevity researchers adds credibility but doesn't guarantee success. Investors should closely monitor upcoming FDA communications and any progress towards clinical trials, as these will be critical milestones for ANEW's valuation.
ANEW's approach to leveraging gene therapy for longevity and neurodegenerative diseases is at the cutting edge of biotechnology. The focus on the Klotho gene, often called the "anti-aging gene," aligns with current trends in longevity research. However, the technical challenges in developing effective and safe gene therapies are significant. While ANEW has secured patents, the practical application of this technology remains to be proven. The company's plan to study Okinawan centenarians' blood samples is innovative, but translating these findings into viable therapies will require substantial technological advancements. Investors should be aware that the timeline for bringing such advanced therapies to market can be lengthy and uncertain.
Company will use novel, patented Klotho Gene (s-KL) in studies
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s disease.
ANEW has secured exclusive worldwide rights and issued patents in the USA, Canada, Europe, Hong Kong and China, covering the secreted form of Klotho, known scientifically as s-KL. Klotho is often referred to as “the anti-aging gene.” It is named after the Greek goddess who is said to spin the thread of life.
Existing data supports ANEW’s scientific hypothesis that maintaining high levels of Klotho as we age leads to a long and healthy life (often into the 100s) whereas depleted levels of Klotho may lead to neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s Diseases as well as other age-related disorders including cardiovascular conditions, osteoporosis, and the muscle-wasting disorder, sarcopenia. ANEW hopes to further demonstrate the validity of its hypothesis by examining the stored blood samples of a cohort of people who stayed healthy and reached very old age, many in excess of 100 years, in Okinawa, Japan. Okinawa is one of the famous “Blue Zones” of the world (see the Netflix documentary series “Living to 100”). The results of this study will be compared to a matching cohort of an aging population who have experienced neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s and other age-related disorders.
ANEW is focused on both enhancing the potential for people to experience healthy longevity as well as on the development of cell and gene-based therapies to treat neurodegenerative and age-related disorders based on its patented Klotho technology. The company hopes to obtain FDA agreement in the near future to enter the clinic in at least one indication area. It has also recently announced a partnership with the key scientists involved in the Okinawa Centenarian Research Center for Longevity who are retained as Advisor on longevity and the development of new pharmaceutical treatments. This includes Drs. Craig and Bradley Willcox, authors of the best-selling, Oprah Winfrey recommended, book, “The Okinawa Program: How the World’s Longest-Lived People Achieve Everlasting Health-And How You Can Too.”
Commenting on this development, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW, stated: “Our recent Nasdaq listing will provide us with the opportunity to more expeditiously pursue our development programs to produce cell and gene therapies based on our proprietary Klotho technology. Also, having Drs. Michio Shimabukuro, Richard Allsopp, and Craig and Bradley Willcox of the Okinawa Centenarian Research Center for Longevity Sciences as retained Advisors to our company will be highly important in guiding our development based on their scientific insights in the field of longevity and the data contained in the stored blood samples of Okinawa centenarians.”
About ANEW MEDICAL, INC.
ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer’s and Parkinson’s disease, multiple sclerosis and rare neurodegenerative disorders. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@anewmeds.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
What are ANEW MEDICAL's (WENA) main goals for its gene therapy development?
What is the significance of the Klotho gene in ANEW MEDICAL's (WENA) research?
How is ANEW MEDICAL (WENA) planning to validate its Klotho gene hypothesis?
Who are the key scientific advisors partnering with ANEW MEDICAL (WENA)?
